纤溶酶原激动抑制剂-1基因4G/5G多态性与冠心病

采用特异性引物多聚合酶链式反应方法 ,检测了 1 2 3例冠心病患者和 1 72例健康对照者的纤溶酶原激动抑制剂 1 (PAI 1 )基因 ,并同时测定血液PAI 1质量浓度和活性 ,体质量指数、胆固醇和三酰甘油 ,探讨了PAI 1基因4G/5G多态性与冠心病的相关性。结果显示 ,冠心病组的缺失型纯合子 4G/4G型 ( 47.2 %)明显多于对照组 ( 2 2 .1 %,P <0 .0 5) ,4G/4G组的PAI 1质量浓度〔( 40 .87± 0 .99) μg/L)〕和PAI活性〔( 750± 350 )U/L〕均高于 5G/5G组〔( 38.1 4± 1 .0 ) μg/L ,( 650± 2 70 )U/L ,P <0 .0 5〕。提示PAI 1基因 4G/5G多态性与PAI 1质量浓度及活性具有相关性 ,并与冠心病的发病过程有关

The 4G/5G Polymorphism ofthe Plasminogen Activator Inhibitor-1 Gene in Patients with Coronary Heart Disease

WT5BZ]To investigate the relationship between 4G/5G polymorphism of the plasminogen activator inhibitor-1(PAI-1)gene and coronary heart disease(CHD), genotype at this polymorphism was determined in 123 cases with CHD and 172 controls by polymerase chain reaction using the allele specific primers. Plasma PAI-1 antigen level, PAI activity, cholesterol and triglyceride were measured and body mass index was calculated from all the subjects. The group of CHD had a high number of homozygotes for the deleted allele(4G/4G)of the PAI-1 gene compared with the control(47.2% vs 22.1%, P< 0.05). Mean plasma PAI-1 antigen level and PAI activity varied significantly among the 3 genotypes, being higher in 4G/4G subjects than in 5G/5G subjects 〔(40.87±0.99)μg/L〕 vs 〔(38.14±1.0)μg/L〕, 〔(750±350)U/L〕 vs(650±270)U/L, P<0.05). The PAI-1 4G/5G polymorphism correlated with PAI-1 antigen level to some extent accounts for the development of CHD.